CTI BioPharma Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CTI BioPharma Corp.
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
- Other Names / Subsidiaries
- Aequus BioPharma, Inc
- Cell Therapeutics, Inc.
- CTI Life Sciences Limited
- Systems Medicine, LLC
- CTI BioPharma Corporation